The report will be delivered in 2-3 business days.

Ovarian Cancer Drugs Global Market Report 2020-30: Covid 19 Impact And Recovery

Starting Price : $ 4000.00 $3200.00 | Pages : 200 | Published : September 2020 | SKU CODE : 7221 | Format :


The ovarian cancer drugs market consists of sales of ovarian cancer drugs to treat ovarian cancer. Ovarian cancer is caused due to abnormal growth of cells in ovary. This industry includes establishments that produce drugs used in chemotherapy, radiation, and surgery for treating ovarian cancer. The ovarian cancer drugs include Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, Platinol (Cisplatin), Paraplatin (Carboplatin), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide) and others.

The global ovarian cancer drugs market is expected to grow from $1.4 billion in 2019 to $1.4 billion in 2020 at a compound annual growth rate (CAGR) of 0.7%. The low growth is mainly due to the COVID-19 outbreak and the measures to contain it. Hospitals across the world have postponed the chemo treatments for cancer patients due to covid positive cases in the hospitals. The sessions are delayed or postponed to prevent patients and staff from unnecessary exposure. The cancer treatment can lower the patient`s ability to fight infection. COVID-19 pandemic is affecting industries across the globe including the pharmaceutical sector. The disruptions due to extended factory closures in various countries, shortage of APIs and other chemicals, rise in prices of key ingredients, and slowed production are the key factors for this low growth. The market is then expected to grow at a CAGR of 19.8% from 2021 and reach $2.9 billion in 2023.

North America was the largest region in the ovarian cancer drugs market in 2018, followed by Europe. This region is expected to remain the largest during the next five years.

The rising incidence of ovarian cancer is driving the ovarian cancer drugs market. In 2018, according to the World Cancer Research Fund International (WCRF), there were nearly 300,000 new ovarian cancer cases recorded globally. Furthermore, ovarian cancer is recorded to be the eighth most commonly occurring cancer in women and the 18th most commonly occurring cancer across the globe. According to a study by The World Ovarian Cancer Coalition 2018, an estimated 55% rise is expected in the number of patients suffering from ovarian cancer by 2035. According to a report on cancer facts and figures 2018, the  estimated number of new cancer cases and deaths in the USA, in 2018 were 1,735,350 and 609,640 respectively. Furthermore, in 2018, there were approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the USA. Thus, the increasing incidence of ovarian cancer cases across the globe drives the ovarian cancer drugs market growth.

Increasing use of biologics and targeted therapies are restraining the Ovarian Cancer drugs market growth. Targeted therapies act as substitutes for drugs as they identify and attack cancer cells rather than destroying normal cells. For example, Bevacizumab is a targeted therapy biologics drugs used to treat Ovarian Cancer. A targeted therapy drug, Zejula was approved by FDA for ovarian cancer, and many targeted therapy drugs such as PARP inhibitors (targeted therapy drug) are undergoing clinical trials and are in drug pipeline. FDA has also approved Genentech’s biologics license for ovarian cancer drugs highlighting the fact many new companies are entering into the biologics ovarian drug cancer market. Hence, the growing popularity of alternatives such as biologics and targeted therapies may hinder the growth of ovarian cancer drugs market.

Drug manufacturing companies in the industry are increasingly innovating and developing combination drugs to treat ovarian cancer drugs. Combination drugs consists of two or more active pharmaceutical ingredients (APIs) that are combined into a single dosage form to treat complex medical conditions. The pharmaceutical companies in the ovarian cancer drugs market are investing on the research and development of innovative products such as combination drugs to reduce manufacturing costs, increase compliance and efficiency, improve medication concordance, increase profitability and reduce side effects. For instance, Roche`s blockbuster tranquilize Avastin (bevacizumab), is a combination drug approved by FDA in 2018, with ingredients such as carboplatin and paclitaxel, which is utilized to treat advance stage (III or IV) ovarian cancer.

The Ovarian cancer drugs market is governed by regulatory framework of agencies such as Food and Administration Agency (FDA) and American Society of Clinical Oncology (ASCO). FDA`s recommendation for ovarian cancer drugs market in the form of guidelines are mentioned within the CFR `s (Code for Federal Regulations) title number 21 under part 312, that contains sub-parts from sub part `A` to sub part `I`. The sub-part `E` deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening and illnesses such as kidney cancer. The sub part `E` also includes guidelines for the monitoring and evaluation of clinical trials of ovarian cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All companies operating in ovarian cancer drugs industry are required to abide to the regulations under FDA.

In January 2019, GlaxoSmithKline (GSK), a UK-based pharmaceutical company, acquired Tesaro for $5.1 billion.  This acquisition would enable GSK to expand its product portfolio with Tesaro’s Zejula, PARP inhibitor and others, improve significant opportunities in strengthening GSK’s pharmaceutical business by accelerating the build of GSK’s pipeline and commercial capability in oncology. Tesaro, a biopharmaceutical (oncology-focused) company, is involved in manufacturing and marketing ovarian cancer drugs such as  Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor and others, that aid in treating ovarian cancer. Tesaro was founded in 2010 and headquartered in Waltham, Massachusetts, USA.

The major players covered in the global ovarian cancer drugs market are AstraZeneca, Roche, Tesaro, Clovis Oncology, Boehringer Ingelheim, Amgen, GlaxoSmithKline, F. Hoffmann-La Roche AG, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Johnson & Johnson, Merck KGaA, Syndax Pharmaceuticals, Allergan plc, Celgene, Janssen Pharmaceuticals, Novogen, Genentech , Aetera Zenteris , AbbVie, ImmunoGen, Oasmia Pharmaceuticals, Spectrum Pharmaceuticals, Abraxane, DelMar Pharmaceuticals Inc, Alkeran, Novartis.

The countries covered in the global ovarian cancer drugs market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia.

The regions covered in the global ovarian cancer drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The global ovarian cancer drugs market is segmented - 1) By Tumor Type: Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor. 2) By Distribution Channel: Hospital Pharmacies, Drug Stores, Others. 3) By Drug Type: Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR inhibitors, PARP inhibitors, Antineoplastics, Others.

    1. Executive Summary

    2. Ovarian Cancer Drugs Market Characteristics

    3. Ovarian Cancer Drugs Market Size And Growth

    3.1. Global Ovarian Cancer Drugs Historic Market, 2015-2019, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Ovarian Cancer Drugs Forecast Market, 2019-2023F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Ovarian Cancer Drugs Market Segmentation

    4.1. Global Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Epithelial Ovarian Cancer

    Ovarian Low Malignant Potential Tumor

    Germ Cell Tumor

    Sex Cord-Stromal Tumor

    4.2. Global Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Hospital Pharmacies

    Drug Stores

    Others

    4.3. Global Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Alkylating Agents

    Mitotic Inhibitors

    Antirheumatics

    Antipsoriatics

    VEGF/VEGFR inhibitors

    PARP inhibitors

    Antineoplastics

    Others

    5. Ovarian Cancer Drugs Market Regional And Country Analysis

    5.1. Global Ovarian Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    5.2. Global Ovarian Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Ovarian Cancer Drugs Market  

    6.1. Asia-Pacific Ovarian Cancer Drugs Market Overview  

    6.2. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6.3. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6.4. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    7. China Ovarian Cancer Drugs Market  

    7.1. China Ovarian Cancer Drugs Market Overview  

    7.2. China Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    7.3. China Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    7.4. China Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    8. India Ovarian Cancer Drugs Market  

    8.1. India Ovarian Cancer Drugs Market Overview  

    8.2. India Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    8.3. India Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    8.4. India Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9. Japan Ovarian Cancer Drugs Market  

    9.1. Japan Ovarian Cancer Drugs Market Overview  

    9.2. Japan Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9.3. Japan Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9.4. Japan Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10. Australia Ovarian Cancer Drugs Market  

    10.1. Australia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10.2. Australia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10.3. Australia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11. Indonesia Ovarian Cancer Drugs Market  

    11.1. Indonesia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11.2. Indonesia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11.3. Indonesia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12. South Korea Ovarian Cancer Drugs Market  

    12.1. South Korea Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12.2. South Korea Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12.3. South Korea Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13. Western Europe Ovarian Cancer Drugs Market  

    13.1. Western Europe Ovarian Cancer Drugs Market Overview

    13.2. Western Europe Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13.3. Western Europe Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13.4. Western Europe Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14. UK Ovarian Cancer Drugs Market  

    14.1. UK Ovarian Cancer Drugs Market Overview

    14.2. UK Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14.3. UK Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14.4. UK Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15. Germany Ovarian Cancer Drugs Market  

    15.1. Germany Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15.2. Germany Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15.3. Germany Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16. France Ovarian Cancer Drugs Market  

    16.5. France Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16.6. France Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16.7. France Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17. Eastern Europe Ovarian Cancer Drugs Market  

    17.1. Eastern Europe Ovarian Cancer Drugs Market Overview

    17.2. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17.3. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17.4. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18. Russia Ovarian Cancer Drugs Market  

    18.1. Russia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18.2. Russia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18.3. Russia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19. North America Ovarian Cancer Drugs Market  

    19.1. North America Ovarian Cancer Drugs Market Overview

    19.2. North America Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19.3. North America Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19.4. North America Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20. USA Ovarian Cancer Drugs Market  

    20.1. USA Ovarian Cancer Drugs Market Overview

    20.2. USA Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20.3. USA Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20.4. USA Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21. South America Ovarian Cancer Drugs Market  

    21.1. South America Ovarian Cancer Drugs Market Overview

    21.2. South America Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21.3. South America Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21.4. South America Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22. Brazil Ovarian Cancer Drugs Market  

    22.1. Brazil Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22.2. Brazil Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22.3. Brazil Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23. Middle East Ovarian Cancer Drugs Market  

    23.1. Middle East Ovarian Cancer Drugs Market Overview

    23.2. Middle East Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23.3. Middle East Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23.4. Middle East Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24. Africa Ovarian Cancer Drugs Market  

    24.1. Africa Ovarian Cancer Drugs Market Overview

    24.2. Africa Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24.3. Africa Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24.4. Africa Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    25. Ovarian Cancer Drugs Market Competitive Landscape And Company Profiles

    25.1. Ovarian Cancer Drugs Market Competitive Landscape

    25.2. Ovarian Cancer Drugs Market Company Profiles

    25.2.1. AstraZeneca

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2. Roche

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3. Tesaro

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4. Clovis Oncology

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5. Boehringer Ingelheim

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Ovarian Cancer Drugs Market

    27. Ovarian Cancer Drugs Market Trends And Strategies

    28. Product Pipeline Analysis

    29. Ovarian Cancer Drugs Market Future Outlook and Potential Analysis

    30. Appendix

    30.1. Abbreviations

    30.2. Currencies

    30.3. Research Inquiries

    30.4. The Business Research Company

    30.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2014-2018, $ Billion
  • Table 2: Global Forecast Market Growth, 2019-2023F, 2025F, 2030F, $ Billion
  • Table 3: Global Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 4: Global Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 5: Global Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 6: Global Ovarian Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7: Global Ovarian Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 9: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 10: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 11: China, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 12: China, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 13: China, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 14: India, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 15: India, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 16: India, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 17: Japan, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 18: Japan, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 19: Japan, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 20: Australia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 21: Australia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 22: Australia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 23: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 24: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 25: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 26: South Korea, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 27: South Korea, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 28: South Korea, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 29: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 30: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 31: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 32: UK, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 33: UK, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 34: UK, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 35: Germany, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 36: Germany, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 37: Germany, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 38: France, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 39: France, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 40: France, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 41: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 42: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 43: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 44: Russia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 45: Russia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 46: Russia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 47: North America, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 48: North America, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 49: North America, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 50: USA, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 51: USA, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 52: USA, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 53: South America, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 54: South America, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 55: South America, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 56: Brazil, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 57: Brazil, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 58: Brazil, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 59: Middle East, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 60: Middle East, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 61: Middle East, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 62: Africa, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 63: Africa, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 64: Africa, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 65: AstraZeneca Financial Performance
  • Table 66: Roche Financial Performance
  • Table 67: Tesaro Financial Performance
  • Table 68: Clovis Oncology Financial Performance
  • Table 69: Boehringer Ingelheim Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2014-2018, $ Billion
  • Figure 2: Global Forecast Market Growth, 2019-2023F, 2025F, 2030F, $ Billion
  • Figure 3: Global Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 4: Global Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 5: Global Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 6: Global Ovarian Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 7: Global Ovarian Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 9: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 10: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 11: China, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 12: China, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 13: China, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 14: India, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 15: India, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 16: India, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 17: Japan, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 18: Japan, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 19: Japan, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 20: Australia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 21: Australia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 22: Australia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 23: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 24: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 25: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 26: South Korea, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 27: South Korea, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 28: South Korea, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 29: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 30: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 31: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 32: UK, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 33: UK, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 34: UK, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 35: Germany, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 36: Germany, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 37: Germany, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 38: France, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 39: France, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 40: France, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 41: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 42: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 43: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 44: Russia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 45: Russia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 46: Russia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 47: North America, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 48: North America, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 49: North America, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 50: USA, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 51: USA, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 52: USA, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 53: South America, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 54: South America, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 55: South America, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 56: Brazil, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 57: Brazil, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 58: Brazil, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 59: Middle East, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 60: Middle East, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 61: Middle East, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 62: Africa, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 63: Africa, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 64: Africa, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 65: AstraZeneca Financial Performance
  • Figure 66: Roche Financial Performance
  • Figure 67: Tesaro Financial Performance
  • Figure 68: Clovis Oncology Financial Performance
  • Figure 69: Boehringer Ingelheim Financial Performance
New Drug Innovations In The Pharmaceuticals Market
Antithrombotic Drugs Are Being Used To Prevent Various Disorders
Increasing Rate Of The Elder Population Is Driving The Ophthalmology Drugs Market
Innovations In The Diabetes Therapies Market
Allergan plc- One Of The Largest Companies In The Global Drugs For Benign Prostatic Hypertrophy Market
Innovation And Development Of Combination Drugs To Enhance Growth Of The Ovarian Cancer Drugs Market
The Global Prostate Cancer Drugs Market Will Reach Around $10 By 2022
Antivirals Are The Largest And Fastest Growing Segment Of The Anti-Infective Drugs Market
Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
Ophthalmology Drugs Market - By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Dry Eye Medication Market - By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Coronavirus (COVID-19) Current Therapy Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Drug Associated APIs Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Vaccine & Therapeutics Clinical Trial Analysis 2020
View Report
COVID19 Vaccine And Therapeutics Pipeline Analysis 2020
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)